Vitamin D Supplementation in Conscripts
Primary Purpose
Vitamin D Deficiency, Military Activity
Status
Completed
Phase
Not Applicable
Locations
Estonia
Study Type
Interventional
Intervention
Vitamin D3 (1200 IU/30µg)
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Vitamin D Deficiency
Eligibility Criteria
Inclusion Criteria:
- participating in military service at the Estonian Defence Forces
- voluntarity to participate in the study
Exclusion Criteria:
- inability to continue military service for any reason, during the 7 month follow-up period
Sites / Locations
- Kuperjanov Infantry Battalion, Estonian Defence Forces
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Intervention
Control
Arm Description
Received vitamin D3 capsules (1200 IU/30µg).
Received placebo (oil capsules).
Outcomes
Primary Outcome Measures
Prevalence of vitamin D deficence
Prevalence of vitamin D deficence as measured serum vitamin D 25(OH)D concentration. Vitamin D was considered as sufficient if the se-rum 25(OH)D concentration was ≥75 nmol/L, insufficient if <75 nmol/L, and deficient if <50 nmol/L.
Secondary Outcome Measures
Full Information
NCT ID
NCT04359524
First Posted
April 21, 2020
Last Updated
September 12, 2021
Sponsor
Leho Rips
Collaborators
Estonian Defence Forces, University of Tartu
1. Study Identification
Unique Protocol Identification Number
NCT04359524
Brief Title
Vitamin D Supplementation in Conscripts
Official Title
Fitness and Health Characteristics in Conscripts With Supplementation of Vitamin D
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
October 1, 2016 (Actual)
Primary Completion Date
April 20, 2017 (Actual)
Study Completion Date
April 25, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Leho Rips
Collaborators
Estonian Defence Forces, University of Tartu
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A longitudinal, triple-blinded, randomized, placebo-controlled trial, with a 7-month follow-up period is conducted between October 2016 to April 2017.
Detailed Description
Body mass (kg) and height (cm) is measured by the same person at the medical center using standardized equipment and the body mass index (BMI) is calculated in kg/m2.
Computed randomization is used to divide conscripts into two groups; either the intervention group or the control group. Both types of capsules are administered once per day in the morning before breakfast for 7 months. Standardized coded packages (3 per conscript) and capsules (100 per package) are manufactured on a special order by Innopharma A/S (Denmark). No commercial sponsoring is involved.
The key of the package code is stored in the computer database until unblinding of the results.
Laboratory measurements Serum samples for clinical chemistry analysis are collected into serum clot activator tubes. Calcium measurements are performed using spectrophotometry method. Ionized calcium measurements are performed using ion selective electrodes. The direct chemiluminescent immunoassay method is used for measurement of PTH. 25(OH)D is measured using direct chemiluminescent immunoassay method.
Power calculation The primary variable of the study is the level of 25 (OH)D in the serum. In the power analysis a difference of 20 nmol/L between the intervention and the control group is considered to be meaningful to detect. If the SD would be 25 nmol/L, then 26 participants would be needed in each group to reach a power of 80%.
Statistical analysis The distribution of blood serum values in the study groups is described by means and standard deviations (SD). Differences in mean values of the variables of interest between the groups are evaluated using Welch t-test. The within group comparisons over time are performed using paired t-test with Bonferroni correction. Distributions of categorical variables are described by absolute numbers and percentages and compared between groups using the Fisher exact test. Statistical significance is set at the 0.05 probability level.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency, Military Activity
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Triple blinded randomized placebo-controlled study
Masking
ParticipantCare ProviderInvestigator
Masking Description
Computed randomization was used to divide conscripts into two groups; either the intervention group, who received vitamin D3 capsules (1200 IU/30µg) or the control group, who received placebo (oil capsules).
Allocation
Randomized
Enrollment
63 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Active Comparator
Arm Description
Received vitamin D3 capsules (1200 IU/30µg).
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Received placebo (oil capsules).
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3 (1200 IU/30µg)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo oil capsule
Primary Outcome Measure Information:
Title
Prevalence of vitamin D deficence
Description
Prevalence of vitamin D deficence as measured serum vitamin D 25(OH)D concentration. Vitamin D was considered as sufficient if the se-rum 25(OH)D concentration was ≥75 nmol/L, insufficient if <75 nmol/L, and deficient if <50 nmol/L.
Time Frame
0, 2, 5 and 7 months of recruitment
Other Pre-specified Outcome Measures:
Title
serum parathyroid hormone
Description
serum parathyroid hormone concentration (pmol/l)
Time Frame
0, 2, 5 and 7 months of recruitment
Title
serum calcium
Description
serum calcium (Ca) concentration (mmol/l)
Time Frame
0, 2, 5 and 7 months of recruitment
Title
serum ionized calcium
Description
serum ionized calcium (Ca-i) concentration (mmol/l)
Time Frame
0, 2, 5 and 7 months of recruitment
Title
Hand Grip Strength
Description
Hand grip strength is determined by isometric contraction while standing, upper limb away from the body, using a hand dynamometer (Lafayette Instrument Co., USA).
Time Frame
0, 2, 5 and 7 months of recruitment
Title
Testosterone
Description
Serum testosterone concentration (nmol/l)
Time Frame
0, 2, 5 and 7 months of recruitment
Title
Cortisol
Description
Serum cortisol concentration (nmol/l)
Time Frame
0, 2, 5 and 7 months of recruitment
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
27 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
participating in military service at the Estonian Defence Forces
voluntarity to participate in the study
Exclusion Criteria:
inability to continue military service for any reason, during the 7 month follow-up period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helena Gapeyeva, MD, PhD
Organizational Affiliation
University of Tartu
Official's Role
Study Director
Facility Information:
Facility Name
Kuperjanov Infantry Battalion, Estonian Defence Forces
City
Võru
State/Province
Võrumaa
ZIP/Postal Code
50400
Country
Estonia
12. IPD Sharing Statement
Learn more about this trial
Vitamin D Supplementation in Conscripts
We'll reach out to this number within 24 hrs